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INTRODUCTION
This chapter makes treatment recommendations for adults
with pauci-immune focal and segmental necrotizing GN with
or without systemic vasculitis, and with or without circu-
lating ANCA. The cost implications for global application of
this guideline are addressed in Chapter 2.
13.1: Initial treatment of pauci-immune focal and seg-
mental necrotizing GN
13.1.1: We recommend that cyclophosphamide and
corticosteroids be used as initial treatment. (1A)
13.1.2: We recommend that rituximab and cortico-
steroids be used as an alternative initial
treatment in patients without severe disease
or in whom cyclophosphamide is contra-
indicated. (1B)
13.2: Special patient populations
13.2.1: We recommend the addition of plasma-
pheresis for patients requiring dialysis or
with rapidly increasing SCr. (1C)
13.2.2: We suggest the addition of plasmapheresis for
patients with diffuse pulmonary hemorrhage.
(2C)
13.2.3: We suggest the addition of plasmapheresis
for patients with overlap syndrome of ANCA
vasculitis and anti-GBM GN, according to
proposed criteria and regimen for anti-GBM
GN (see Chapter 14). (2D)
13.2.4: We suggest discontinuing cyclophosphamide
therapy after 3 months in patients who
remain dialysis-dependent and who do not
have any extrarenal manifestations of disease.
(2C)
BACKGROUND
Small-vessel vasculitis encompasses a group of diseases
characterized by necrotizing inflammation of the small
vessels: arterioles, capillaries, and venules. They are charac-
terized by little or no deposition of immune complexes in
the vessel wall (pauci-immune). Medium or large vessels may
occasionally be involved. Pauci-immune small vessel vasculi-
tides include granulomatosis with polyangitis (Wegener’s),
microscopic polyangiitis, and Churg-Strauss syndrome. The
characteristic kidney lesion in these conditions is pauci-
immune focal and segmental necrotizing and crescentic
glomerulonephritis (NCGN). Active pauci-immune small-
vessel vasculitis is typically associated with circulating ANCA
(ANCA vasculitis). NCGN may also occur without extrarenal
manifestations of disease.
The clinical manifestations associated with NCGN include
microscopic hematuria with dysmorphic red blood cells
and red cell casts, and proteinuria that is usually moderate
(1–3 g/d). Pauci-immune NCGN is frequently associated with
a rapidly declining GFR over days or weeks. A minority of
patients may present with a more indolent course with
asymptomatic microscopic hematuria and minimal protein-
uria, which may progress over months.
Patients with systemic vasculitis may present with a
variety of extrarenal clinical manifestations affecting one or
several organ systems, with or without kidney involvement.
Commonly involved systems are upper and lower respiratory
tract, skin, eyes, and the nervous system. Severe pulmonary
hemorrhage affects about 10% of patients with ANCA GN,
and is associated with an increased risk of death.704 The need
to treat extrarenal vasculitis may impinge on treatment
choices for renal vasculitis.
About 90% of patients with small-vessel vasculitis or
pauci-immune NCGN have ANCA, directed primarily to the
neutrophil granule proteins myeloperoxidase (MPO) or
proteinase 3 (PR3).
The treatment recommendations in this guideline derive
from studies of patients with ANCA vasculitis and/or GN.
About 10% of patients presenting with signs and symptoms
of microscopic polyangiitis, granulomatosis with polyangitis
(Wegener’s), or pauci-immune NCGN are persistently
ANCA-negative. These patients are treated similarly to
ANCA-positive patients, although no study has focused
specifically on the treatment of ANCA-negative patients.
RATIONALE
K Without therapy, ANCA vasculitis with GN is associated
with very poor outcomes.
K There is high-quality evidence for treatment with
corticosteroids and cyclophosphamide that has dramati-
cally improved the short- and long-term outcomes of
ANCA vasculitis associated with systemic disease.
K Immunosuppressive therapy may not be appropriate in
patients with severe NCGN already requiring dialysis.
K All patients with extrarenal manifestations of disease
should receive immunosuppressive therapy regardless of
the degree of kidney dysfunction.
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K There is high-quality evidence that plasmapheresis
provides additional benefit in those with severe NCGN.
K There is low-quality evidence that plasmapheresis pro-
vides additional benefit for diffuse pulmonary hemor-
rhage.
K There is evidence that rituximab is not inferior to
cyclophosphamide in induction therapy.
Recommended treatment regimens are shown in Table 30.
Without therapy, ANCA vasculitis with GN is associated
with very poor outcomes. Treatment with corticosteroids and
cyclophosphamide has dramatically improved the short- and
long-term outcomes of ANCA vasculitis associated with
systemic disease. Treatment with immunosuppressive therapy
is therefore considered indicated in all cases of ANCA
vasculitis and GN. The rare possible exception relates to
patients with severe kidney-limited disease, in the absence of
extrarenal manifestations of small-vessel vasculitis. Thus, in
patients with severe pauci-immune NCGN requiring dialysis,
the question arises as to whether the risks of therapy are
greater than the likelihood of recovering kidney function, or
whether there is a point beyond which immunosuppressive
therapy is futile.
Cohort studies did not detect a level of kidney function
below which therapy can be deemed futile, as remission
occurred in about 57% of patients with a GFR of 10ml/min
or less at presentation.706 Of 69 patients who presented
dialysis-dependent at the beginning of the Methylpredniso-
lone or Plasma Exchange (MEPEX) trial,707 44% were
dialysis-independent at 12 months, and the point at which
the chance of dying from therapy with plasmapheresis
exceeded that of the chance of recovery was reached only in
patients with severe tubular atrophy and injury of nearly all
glomeruli.708 This study suggests that, in the absence of
extrarenal manifestations of disease, treatment is warranted
in all but patients with extreme glomerular obsolescence and
severe tubulointerstitial scarring. All patients with extrarenal
manifestations of disease should receive immunosuppressive
therapy, regardless of the degree of kidney dysfunction.
Disease Activity
Kidney manifestations of active GN are a progressive decline
in kidney function, ongoing proteinuria with the continued
presence of dysmorphic red cells in the urine, and red
cell casts.
Remission is defined by the absence of manifestations of
vasculitis and GN disease activity. For GN, it is defined as the
absence of microscopic hematuria and a stable or improved
proteinuria and GFR. Disease activity of ANCA vasculitis
represents signs or symptoms attributable to active disease in
any organ system.
Cyclophosphamide
The addition of cyclophosphamide to corticosteroids in induc-
tion therapy improved the remission rate from about 55% to
about 85%, and decreased the relapse rate three-fold.706,709
Pulse i.v. and daily oral regimens for cyclophosphamide
are associated with similar remission and relapse rates
(Online Suppl Tables 96–99).705 Considerations in choosing
one approach over the other are: compliance, cost, cumula-
tive dose of cyclophosphamide, frequency of leucopenia, and
infection. For the same duration of therapy, patients in the
i.v. pulse arm received about half the cumulative amount of
cyclophosphamide as in the daily oral arm.705 In a meta-
analysis of four RCTs, pulse i.v. cyclophosphamide compared
to daily oral cyclophosphamide was associated with less
leucopenia (RR 0.53 95%CI 0.36-0.77; P¼ 0.0009), fewer
infections (not significant), increased risk of relapse (RR 1.79,
95%CI 1.11-2.87; P¼ 0.02), and a trend toward an increased
number of patient requiring renal replacement therapy.710
Table 30 | Recommended treatment regimens for ANCA vasculitis with GN
Agent Route Initial dose
Cyclophosphamidea i.v. 0.75 g/m2 q 3–4 weeks.
Decrease initial dose to 0.5 g/m2 if age 460 years or GFR o20ml/min per 1.73m2.
Adjust subsequent doses to achieve a 2-week nadir leukocyte count 43000/mm3.
Cyclophosphamideb p.o. 1.5–2mg/kg/d, reduce if age 460 years or GFR o20ml/min per 1.73m2.
Adjust the daily dose to keep leucocyte count 43000/mm3.
Corticosteroids i.v. Pulse methylprednisolone: 500mg i.v. daily 3 days.
Corticosteroids p.o. Prednisone 1mg/kg/d for 4 weeks, not exceeding 60mg daily.
Taper down over 3–4 months.
Rituximabc i.v. 375mg/m2 weekly 4.
Plasmapheresisd 60ml/kg volume replacement.
Vasculitis: Seven treatments over 14 days If diffuse pulmonary hemorrhage, daily until the bleeding stops, then every
other day, total 7–10 treatments.
Vasculitis in association with anti-GBM antibodies: Daily for 14 days or until anti-GBM antibodies are undetectable.
ANCA, antineutrophil cytoplasmic antibody; GBM, glomerular basement membrane; GFR, glomerular filtration rate; GN, glomerulonephritis; i.v., intravenous; p.o., orally.
aGiven with pulse and oral steroids. An alternative i.v. cyclophosphamide dosing schema is 15mg/kg given every 2 weeks for three pulses, followed by 15mg/kg given every
3 weeks for 3 months beyond remission, with reductions for age and estimated GFR.705
bGiven with pulse and oral steroids.
cGiven with pulse and oral steroids.
dNot given with pulse methylprednisolone. Replacement fluid is 5% albumin. Add 150–300ml fresh frozen plasma at the end of each pheresis session if patients have
pulmonary hemorrhage, or have had recent surgery, including kidney biopsy.
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Based on the RCT of maintenance therapy comparing
cyclophosphamide to azathioprine, the majority of patients
(77%) achieved remission with oral cyclophosphamide by
3 months, and another 16% between 3 and 6 months.711
Thus, the duration of continuous oral cyclophosphamide
should usually be limited to 3 months, with a maximum of
6 months. Whether this duration of treatment applies to
pulse i.v. cyclophosphamide is inferred, but not tested. The
only study of a short (6-month) vs. long (12-month) course
of cyclophosphamide was not powered to detect a difference
in outcome.712 A retrospective cohort analysis did not
indicate that longer treatment with cyclophosphamide
reduces the rate of relapse.706
Among patients who require dialysis, those who recover
sufficient kidney function nearly always do so within the first
3 months of treatment.708,709 Therefore, in patients who are
still dialysis-dependent after 3 months and who have no
evidence of ongoing extrarenal manifestations of active
vasculitis, we suggest discontinuing cyclophosphamide therapy.
Pulse Methylprednisolone
The value of pulse methylprednisolone induction therapy has
not been tested directly. The rationale for pulse methyl-
prednisolone is related to its rapid anti-inflammatory effect.
High-dose methylprednisolone may also contribute to a
rapid reduction in ANCA-producing plasma cells. The
only randomized evaluation of pulse methylprednisolone
(3 1000mg) was in the setting of the MEPEX trial, where it
was compared to plasmapheresis as adjunctive therapy to oral
corticosteroids and oral cyclophosphamide.707 In that trial,
pulse methylprednisolone was less efficacious than plasma-
pheresis in preserving kidney function. There are no data that
1000mg daily for 3 days is better than 500mg; this lower
dose is widely used in clinical practice, and the higher dose
may be associated with increased short- and long-term risks
of infection and other complications of steroids.
Rituximab
Two RCTs examined rituximab as first-line induction
therapy for ANCA vasculitis (Online Suppl Tables 100-102).
In the RITUXVAS trial, 44 patients with newly diagnosed
ANCA vasculitis were randomized 3:1 to either rituximab
(375mg/m2 weekly 4) in addition to cyclophosphamide
(15mg/kg i.v., 2 weeks apart for a total of two doses); or to
cyclophosphamide (15mg/kg i.v. every 2 weeks 3, then
every 3 weeks for a maximum total of 10 doses).713 Both
groups received the same regimen of methylprednisolone
1000mg i.v. followed by oral corticosteroids. Rates of
remission were similar (76% with rituximab group vs. 82%
with cyclophosphamide), as were rates of serious adverse
events.713
In Rituximab for the Treatment of Wegener’s Granulo-
matosis and Microscopic Polyangiitis (RAVE), 197 patients
were randomized to treatment with either rituximab
(375mg/m2 infusions once weekly for 4 weeks) or cyclophos-
phamide (2mg/kg/d orally) for months 1-3, followed by
azathioprine (2mg/kg/d orally) for months 4-6.714 All
patients received one to three i.v. pulses of methylpredniso-
lone (1000mg each) followed by the same oral corticosteroid
regimen. There was no significant difference between the two
treatment groups in rates of complete remission at 6 months,
adverse events, or relapse rates. The RAVE trial excluded
patients with severe alveolar hemorrhage or severe kidney
dysfunction (SCr 44mg/dl [4354 mmol/l]), so the role of
rituximab for such patients remains unknown.
Rituximab shows equivalent efficacy to cyclophosphamide
in initial therapy and the evidence does not suggest a
difference in rates of adverse effects. However, analysis of the
long-term outcomes, including safety, is still awaited. In
addition, the very high cost of rituximab compared to
cyclophosphamide limits its application from a global
perspective.
Plasmapheresis
The addition of plasmapheresis to initial therapy with
corticosteroids and cyclophosphamide is indicated for patients
presenting with either advanced kidney failure (SCr45.66mg/dl
[4500mmol/l]) or with diffuse alveolar hemorrhage.
In a large, multicenter controlled trial,707 137 patients with
a new diagnosis of ANCA vasculitis confirmed by kidney
biopsy were randomly assigned to either seven treatments of
plasmapheresis, or three doses of 1000mg of i.v. methyl-
prednisolone. Both groups received standard therapy with
oral cyclophosphamide and oral prednisone followed by
azathioprine for maintenance therapy. Plasmapheresis was
associated with a significantly higher rate of kidney recovery
at 3 months (69% of patients with plasmapheresis vs. 49%
with i.v. methylprednisolone), and with dialysis-free survival
at 12 months. Whether duration of plasmapheresis should be
tailored to ANCA titers has not been studied.
Studies of plasmapheresis as adjunctive therapy in
patients with SCr o5.66mg/dl (o500 mmol/l) have not
shown benefit, but were underpowered to provide definitive
evidence.715,716 A large RCT of adjunctive therapy with
plasmapheresis is currently underway (clinicaltrials.gov
identifier NCT00987389).
Plasmapheresis for Patients with Diffuse Alveolar
Hemorrhage
The impact of plasmapheresis in patients with diffuse,
severe alveolar hemorrhage is the reduction of mortality,
based on retrospective case series.716,717 Although the
strength of supportive data is low (retrospective case series
without controls), the impact of such treatment is high
(less mortality).709,718 Whether patients with ‘‘mild’’ alveolar
hemorrhage (small focal infiltrate without or with mild
hypoxemia) require plasmapheresis is unknown.
Patients with ANCA Vasculitis: Anti-GBM GN Overlap
Syndrome
The recommendation for plasmapheresis, in addition to
corticosteroids and cyclophosphamide for patients with both
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circulating ANCA and anti-GBM antibodies, is based on
the rationale for the treatment of anti-GBM GN. About
one-third of patients with anti-GBM disease also have
ANCA antibodies, usually directed against MPO. Patients
with ANCA/anti-GBM overlap have a worse outcome than
patients with ANCA vasculitis alone, or anti-GBM alone.719
MMF
There are insufficient data to support the use of MMF
for induction therapy in ANCA vasculitis. Although small
uncontrolled studies report remission rates similar to those
reported with corticosteroids and cyclophosphamide,720
relapses have been reported, despite continued use of MMF.721
The only controlled study to date of MMF (1.5-2 g/d) vs.
cyclophosphamide (monthly i.v. pulse of 0.75-1 g/m2)
includes 35 patients from China,722 four of whom were lost
to follow-up (all in the cyclophosphamide group). When
patients lost to follow-up were excluded from the analysis,
the rates of remission were similar in the two groups. No data
on follow-up beyond 6 months is provided in this study. A
larger RCT of MMF vs. i.v. cyclophosphamide for induction
treatment is currently underway (clinicaltrials.gov identifier
NCT00414128).
13.3: Maintenance therapy
13.3.1: We recommend maintenance therapy in
patients who have achieved remission. (1B)
13.3.2: We suggest continuing maintenance therapy
for at least 18 months in patients who remain
in complete remission. (2D)
13.3.3: We recommend no maintenance therapy in
patients who are dialysis-dependent and have
no extrarenal manifestations of disease. (1C)
13.4: Choice of agent for maintenance therapy
13.4.1: We recommend azathioprine 1-2mg/kg/d
orally as maintenance therapy. (1B)
13.4.2: We suggest that MMF, up to 1 g twice daily, be
used for maintenance therapy in patients who
are allergic to, or intolerant of, azathioprine.
(2C)
13.4.3: We suggest trimethoprim-sulfamethoxazole as
an adjunct to maintenance therapy in patients
with upper respiratory tract disease. (2B)
13.4.4: We suggest methotrexate (initially 0.3mg/kg/wk,
maximum 25mg/wk) for maintenance therapy
in patients intolerant of azathioprine and MMF,
but not if GFR iso60ml/min per 1.73m2. (1C)
13.4.5: We recommend not using etanercept as
adjunctive therapy. (1A)
BACKGROUND
The indications for maintenance therapy are not well
defined. The goal of maintenance therapy is to decrease the
incidence and severity of relapsing vasculitis. With the excep-
tion of a small trial with trimethoprim-sulfamethoxazole (see
Rationale), no placebo-controlled RCT has studied the
benefit of maintenance therapy, although RCTs have com-
pared the efficacy of different maintenance regimens. There-
fore, the likely benefit of maintenance therapy depends on the
assessment of the risk of relapse, which differs among various
subgroups of patients. For example, the risk of low-dose
maintenance immunosuppression in a frail, elderly patient
has to be weighed against the very high risk for such a patient
of severe relapse. Maintenance immunosuppressive therapy is
justified in patients at high risk of relapse, but the potential
benefit of maintenance therapy may be low in patients who
have a low likelihood of relapse.
RATIONALE
K There is moderate-quality evidence that maintenance
therapy is required in those at high risk of relapse or who
have received less than 6 months induction treatment
with cyclophosphamide.
K There is low-quality evidence that the duration of
maintenance therapy should be at least 18 months.
K There is moderate-quality evidence that azathioprine is
the preferred maintenance immunosuppressive agent,
being equivalent in efficacy to cyclophosphamide in an
RCT with a more favorable adverse-effect profile.
K There is moderate-quality evidence that trimethoprim-
sulfamethoxazole as an adjunct to maintenance therapy
reduces the risk of relapse, but only in those with upper
respiratory disease due to vasculitis.
Risk of Relapse
Based on cohort studies, risk factors for relapse include
persistence of PR3-ANCA (compared to MPO-ANCA),
history of upper respiratory tract disease (e.g., sinusitis,
subglottic stenosis), or lower respiratory tract disease (e.g.
alveolar hemorrhage, cavities, or nodules). Patients with any
one of these three risk factors have an approximately 1.7-fold
increased risk of relapse, and those with all three risk factors
have an approximately 4.7-fold increased risk of relapse.706
Patients with persistent PR3-ANCA–positivity at the end
of cyclophosphamide therapy have a 2- to 3-fold increased
risk of relapse, compared to patients who are ANCA-negative
at the end of initial therapy.723 In addition, patients who are
persistently PR3-ANCA–positive are significantly more likely
to relapse within 5 years after diagnosis.723 Among patients
who achieved remission and were switched from cyclopho-
sphamide to azathioprine, those who remained PR3-
ANCA–positive at the time of the switch had a 2.2-fold
increased risk of suffering a relapse when compared to
patients who were PR3-ANCA–negative. No similar data are
available for patients with MPO-ANCA.
It is unknown whether patients with none of the risk
factors for relapse need maintenance immunosuppression.
The risk-benefit ratio of maintenance therapy has not been
evaluated in such patients. The tailoring of maintenance
therapy, based on the risk factors of relapse, has not been
tested in clinical trials.
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Choice of Immunosuppressive Agent for Maintenance
Therapy
The optimal total duration of corticosteroid therapy is
unknown. Some studies have maintained patients on a low
dose of prednisone (7.5mg daily) for 412 months.711 In
other cohort studies, corticosteroids are tapered completely
off by the end of 5 months if the patient is in remission.706
The best available data support the use of azathioprine
1-2mg/kg/d for 6-18 months. This is inferred from an RCT
of azathioprine vs. cyclophosphamide for the maintenance
of remission.711 Although not specifically designed to
demonstrate the ability of azathioprine to prevent relapses
(compared to placebo), the study established that introdu-
cing azathioprine after 3-6 months of cyclophosphamide,
compared to continuing cyclophosphamide for 12 months,
resulted in similar rates of relapse up to 18 months.
Maintenance therapy with azathioprine appears superior
to MMF. In a large RCTof 155 patients with ANCA vasculitis,
who attained remission with cyclophosphamide and cortico-
steroids, those randomized to MMF (2 g/d) vs. azathioprine
(2mg/kg/d) had a higher cumulative incidence of relapse
(HR 1.7; P¼ 0.02).724 We therefore recommend azathioprine
as the first choice for maintenance therapy in ANCA
vasculitis. However, we suggest using MMF in patients who
are allergic to or intolerant of azathioprine.
In a placebo-controlled trial, the use of trimethoprim-
sulfamethoxazole was associated with a decreased rate of
upper airway-relapse.725 The use of trimethoprim-sulfa-
methoxazole had no impact on the rate of relapse in other
organs.
In a large prospective RCT, 12 months maintenance
therapy with methotrexate (0.3mg/kg/wk initially and
progressively increased to 25mg/wk) was compared to
azathioprine (2mg/kg/d) after induction of remission with
cyclophosphamide and corticosteroids.726 The study was not
designed to demonstrate the superiority of methotrexate over
azathioprine in preventing relapses, but to test the hypothesis
that methotrexate would be safer than azathioprine. The rates
of relapse were not significantly different between the
azathioprine- and methotrexate-treated groups (36% and
33%, respectively; P¼ 0.71) with a mean randomization-
to-relapse interval of 20.6±13.9 months. Methotrexate was
not associated with a higher rate of adverse events when
compared to azathioprine (HR 1.65; 95% CI 0.65-4.18;
P¼ 0.29). However, the severity of the adverse effects with
the use of methotrexate was greater; therefore, it is not
recommended in patients with a reduced GFR o30ml/min
per 1.73m2, and the dose should be adjusted in patients with
a GFR o60ml/min per 1.73m2.
The efficacy and safety of the tumor necrosis factor
receptor–Fc fusion protein, etanercept, in the maintenance of
remission among patients with granulomatosis with poly-
angitis (Wegener’s) was evaluated in an RCT in which
etanercept or placebo was added to a regimen of daily oral
cyclophosphamide or methotrexate and corticosteroids.
Etanercept did not reduce the rate or the severity of relapses,
and was associated with a higher rate of solid tumors and is
therefore not recommended.727,728 Although not tested, we
also do not recommend the use of other anti–tumor necrosis
factor agents.
Duration of Maintenance Therapy
There are no direct data to support a recommendation for
the duration of maintenance therapy. The suggestion of
continuing maintenance therapy for 18 months in patients
who remain in complete remission is inferred from the
duration of maintenance therapy used in the CYCAZAREM
trial.711 Some cohort studies, but not others, have suggested a
higher incidence of relapse in the first 18 months after
induction therapy.
In retrospective analyses of patients with ANCA vasculitis,
the relapse rates of vasculitis were about 60% lower in
patients with ESRD, and infections almost twice as frequent
among patients maintained on immunosuppressive agents
with ESRD.727,728 In addition, infections were an important
cause of death in this population. Given the lower risk of
relapse and higher risk of infection and death, the risk-benefit
ratio does not support the routine use of maintenance
immunosuppression therapy in ANCA vasculitis patients on
chronic dialysis, in the absence of active extrarenal disease.
Continued maintenance therapy is associated with the
risks of immunosuppression, bone marrow suppression
(leucopenia, anemia, thrombocytopenia), and possibly in-
creased risk of cancer, notably skin cancer.284
13.5: Treatment of relapse
13.5.1: We recommend treating patients with severe
relapse of ANCA vasculitis (life- or organ-
threatening) according to the same guidelines
as for the initial therapy (see Section 13.1).
(1C)
13.5.2: We suggest treating other relapses of ANCA
vasculitis by reinstituting immunosuppres-
sive therapy or increasing its intensity with
agents other than cyclophosphamide, includ-
ing instituting or increasing dose of cortico-
steroids, with or without azathioprine or
MMF. (2C)
RATIONALE
K Relapse is associated with increased risk of ESRD.
K Relapse is associated with severe or life-threatening
extrarenal damage.
K There is low-quality evidence that relapses are responsive
to reintroduction or increased dosing of immunosup-
pression, but the preferred treatment regimen has not
been defined.
Impact of Relapse
Relapse is defined as the occurrence of increased disease
activity after a period of partial or complete remission. Thus,
a relapse can manifest as a worsening of pre-existing disease
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activity or the recurrence or development of active GN, or
new signs or symptoms of vasculitis in any organ system.
Severe relapse is defined as life- or organ-threatening
relapse. Examples of life-threatening relapse include diffuse
alveolar hemorrhage and severe subglottic stenosis. Examples
of organ-threatening disease are active GN, or a retro-orbital
mass threatening vision.
In a cohort study, patients who had a relapse of GN were
4.7 times more likely to progress to ESRD compared to those
who did not relapse. This increased risk of ESRD associated
with relapse was independent of age, gender, race, ANCA
specificity, and kidney function at the time of initial
biopsy.706
Relapses respond to immunosuppression with corticoster-
oids and cyclophosphamide with a similar response rate as
the initial disease.709 The repeated use of cyclophosphamide
should be based on the severity of the relapse, taking into
account the cumulative dose previously received by the
patient. Severe relapses should be treated with cyclo-
phosphamide, corticosteroids and plasmapheresis (when
indicated) as described in Section 13.1 and Table 30.
Although a ‘‘safe’’ dose of cyclophosphamide has not been
precisely determined, a recent retrospective study suggests
that the risk of malignancy (other than nonmelanoma skin
cancer) increases with cumulative doses of cyclophosphamide
above 36 g.284 Therefore, for patients who have received, or
are approaching a 36 g cumulative dose of cyclophospha-
mide, we suggest treating subsequent relapses with a
rituximab-based regimen.
For patients with a relapse that is not severe (as defined
earlier), immunosuppressive therapy should be increased
while avoiding, if possible, more cyclophosphamide. If such a
relapse occurs when the patient is not receiving maintenance
therapy, treatment may include the reinstitution of corticos-
teroids, azathioprine, or MMF, alone or in combination;
however, there is no RCT evidence to support any of these
regimens. In patients who suffer a relapse while on
maintenance therapy with azathioprine or MMF, one
treatment option is i.v. immunoglobulin. In an uncontrolled
study, the addition of 6-monthly pulses of i.v. immunoglo-
bulin (0.5 g/kg/d 4 days) over background maintenance
immunosuppression was associated with rates of complete
or partial remission of 83% and 63% at 6 and 9 months,
respectively.729 In patients with kidney dysfunction, it is
preferable to use a sucrose-free formulation of i.v. immuno-
globulin in order to minimize the risk of osmotic-induced
AKI.730
Rituximab was more effective than cyclophosphamide
in treating patients with relapsing ANCA vasculitis (OR
1.40; 95% CI 1.03-1.91; P¼ 0.03).714 Although more
experience will be needed with the use of rituximab for
treatment of severe relapses, and although the long-term
safety of rituximab remains uncertain, its use in relapse
may provide an opportunity to minimize cumulative dosage
and avoid the potential long-term toxicity of cyclo-
phosphamide.
13.6: Treatment of resistant disease
13.6.1: In ANCA GN resistant to induction therapy
with cyclophosphamide and corticosteroids,
we recommend the addition of rituximab
(1C), and suggest i.v. immunoglobulin (2C)
or plasmapheresis (2D) as alternatives.
BACKGROUND
Resistance is defined as the persistence of or appearance of
kidney and/or systemic manifestation of vasculitis, while
receiving treatment equal in intensity to initial immunosup-
pressive therapy. Kidney manifestations of resistance include
the continued presence of dysmorphic erythrocyturia and red
blood cell casts, and are associated with a progressive decline
in kidney function. Disease resistance to corticosteroids and
cyclophosphamide occurs in approximately 20% of patients.
RATIONALE
Adjunctive therapy with i.v. immunoglobulin (single course of
a total of 2 g/kg) was evaluated in an RCT in patients with
resistant ANCA vasculitis. Patients treated with i.v. immuno-
globulin had a more rapid decline in disease activity (as
measured by a 50% reduction in Birmingham vasculitis activity
score) and C-reactive protein at 1 and 3 months, but there was
no significant difference between the two groups after 3 months,
with respect to disease activity or frequency of relapse.731
Several small, uncontrolled case series suggest a role for
rituximab in resistant ANCA vasculitis.732–734 In these
reports, rituximab (375mg/m2 i.v. weekly 4, or 500mg
i.v. weekly 4 fixed doses), in conjunction with corticoster-
oids, resulted in remission in the majority of patients, and
was generally well-tolerated.
There has been no trial of plasmapheresis in resistant
ANCA vasculitis, but its value in this setting has been inferred
from the MEPEX study, which demonstrated improved
kidney outcome with plasmapheresis in patients with severe
kidney dysfunction, and studies suggesting decreased mor-
tality with plasmapheresis in patients with diffuse alveolar
hemorrhage (see Recommendation 13.2.2).
13.7: Monitoring
13.7.1: We suggest not changing immunosuppression
based on changes in ANCA titer alone. (2D)
RATIONALE
Available data mostly report the assessment of PR3-ANCA,
with limited data for MPO-ANCA. The data do not support
the contention that PR3-ANCA is clinically useful in
predicting relapse and should not be used (alone) to
alter immunosuppression.735,736 A persistently positive
PR3-ANCA, at the time of switch to maintenance therapy
with azathioprine, is associated with a 2- to 3-fold increased
risk of relapse, and warrants close follow up.723 For patients
who are in clinical remission but remain PR3-ANCA–positive
after 3-4 months of cyclophosphamide and corticosteroids,
continuing cyclophosphamide for up to 6 months may be
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considered; however, there are no data on the risks or benefits
of such an approach. If ANCA titers increase, it may be worth
intensifying patient follow-up.
13.8: Transplantation
13.8.1: We recommend delaying transplantation
until patients are in complete extrarenal
remission for 12 months. (1C)
13.8.2: We recommend not delaying transplantation
for patients who are in complete remission
but are still ANCA-positive. (1C)
RATIONALE
No prospective data are available to assess the likelihood
of recurrent ANCA vasculitis after kidney transplantation,
or the impact of disease activity or that of a positive ANCA
test at the time of transplantation, on patient outcome.
The frequency of recurrent ANCA vasculitis after kidney
transplantation has been assessed in several retrospective
case series. These have revealed a frequency of relapse around
15-20%, although the frequency of recurrent pauci-immune
necrotizing GN is only around 5%.737,738 In the largest
retrospective study of 107 kidney transplant recipients in
the UK, relapses occurred in only 5% of patients.739 By
multivariate analysis, kidney transplantation within 12
months of achieving remission was associated with increased
mortality; the causes of death were not related to recurrent
vasculitis. ANCA positivity at the time of transplantation
does not appear to affect graft or patient survival, or the
frequency of relapse after transplantation.
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